Proteome SciencesCHIX:PRML +7.63% EV-to-OCF is -432.59 as of Jul. 08, 2026. The stock has 6 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Proteome Sciences ranks better than 98.13% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Proteome Sciences's Enterprise Value is £19.90 Mil.
Proteome Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.05 Mil. Therefore, Proteome Sciences's EV-to-OCF for today is -432.59.
The historical rank and industry rank for Proteome Sciences's EV-to-OCF or its related term are showing as below:
CHIX:PRMl'
s EV-to-OCF Range Over the Past 10 Years
Min: -557.79 Med: -8.95 Max: 1196.03
Current: -432.59
During the past 13 years, the highest EV-to-OCF of Proteome Sciences was 1196.03. The lowest was -557.79. And the median was -8.95.
CHIX:PRMl's EV-to-OCF is ranked better than 98.13% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.165
vs CHIX:PRMl: -432.59
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Proteome Sciences's PE Ratio (TTM) for today is calculated as:
Proteome Sciences's share price for today is £0.0141.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Proteome Sciences EV-to-OCF Related Terms
Proteome Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Proteome Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's EV-to-OCF falls into.
Proteome Sciences's current Enterprise Value is £19.90 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (CHIX:PRML) has a EV-to-OCF of -432.59 as of Jul. 08, 2026. According to the industry distribution chart, Proteome Sciences ranks #4 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 1.9%.
Is Proteome Sciences' EV-to-OCF too high?
Proteome Sciences' current EV-to-OCF is -432.59. Based on the distribution chart, Proteome Sciences ranks #4 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Proteome Sciences' EV-to-OCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #4 out of 214 companies for EV-to-OCF. This places Proteome Sciences in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 6.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.17, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current EV-to-OCF is -432.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (CHIX:PRML) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 29.5% below its estimated fair value. The current EV-to-OCF is -432.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Proteome Sciences (CHIX:PRML), the current EV-to-OCF is -432.59 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRML has been successfully added to your 